Ryvu Therapeutics S.A.

WSE:RVU.WA

64.5 (PLN) • At close December 14, 2023
Bedrijfsnaam Ryvu Therapeutics S.A.
Symbool RVU.WA
Munteenheid PLN
Prijs 64.5
Beurswaarde 1,490,987,934
Dividendpercentage 0%
52-weken bereik 49.2 - 72.4
Industrie Biotechnology
Sector Healthcare
CEO Mr. Pawel Tadeusz Przewiezlikowski M.B.A., M.Sc.
Website https://www.ryvu.com

An error occurred while fetching data.

Over Ryvu Therapeutics S.A.

Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute

Vergelijkbare Aandelen

Captor Therapeutics Spolka Akcyjna logo

Captor Therapeutics Spolka Akcyjna

CTX.WA

105 PLN

Mercator Medical S.A. logo

Mercator Medical S.A.

MRC.WA

41.48 PLN

Mabion S.A. logo

Mabion S.A.

MAB.WA

19.28 PLN

BIOTON S.A. logo

BIOTON S.A.

BIO.WA

3.64 PLN

Celon Pharma S.A. logo

Celon Pharma S.A.

CLN.WA

15.96 PLN

Medicalgorithmics S.A. logo

Medicalgorithmics S.A.

MDG.WA

32.35 PLN

Selvita S.A. logo

Selvita S.A.

SLV.WA

59.7 PLN

NEUCA S.A. logo

NEUCA S.A.

NEU.WA

843 PLN

Financiële Gegevens

Cijfers zijn in miljoenen (PLN)

Cijfers zijn in miljoenen (PLN)